Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.39 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770786 | 0.91 | ADRA2A (0.56) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL28046710 | 0.89 | ADRA2A (0.55) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL28046796 | 0.89 | ADRA2A (0.55) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL28046706 | 0.89 | ADRA2A (0.55) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL21067687 | 0.78 | ADRA2A (0.63) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Diphenylamine SCHEMBL27703830 | 0.73 | HSD17B10 (0.71) | POLBKMT2AALDH1A1HSD17B10MEN1 | |
| SCHEMBL14629679 | 0.72 | ADRA2A (0.56) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL1842264 | 0.72 | ADRA2A (0.56) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL5851701 | 0.72 | ADRA2A (0.56) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL708660 | 0.71 | ADRA2A (0.56) | ADRA2AADRA2CADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1833481-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION | 2006-09-21 | — | — | US | disclosed |
| WO-2006065794-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS AND METHODS FOR TREATING PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | FNTB, FNTA, FDPS | ADRA2A 4325/4885ADRA2C 4335/4885ADRA1D 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.